Chatterjee Malay, Chakraborty Tridib, Tassone Pierfrancesco
Department of Pharmaceutical Technology, Division of Biochemistry, Jadavpur University, Calcutta, West-Bengal 700 032, India.
Eur J Cancer. 2006 Jul;42(11):1640-52. doi: 10.1016/j.ejca.2006.02.016. Epub 2006 Jun 23.
Multiple myeloma (MM) is an incurable B-cell malignancy of terminally differentiated plasma cells. Besides conventional treatments, several targeted therapies are emerging for MM. We review recent developments in monoclonal antibodies (MoAbs) and (radio)immunoconjugates-based targeted immunotherapeutic (serotherapies) strategies, as well as skeletal targeted radiotherapy (STR) in MM. MoAbs-based strategies include the targeting of cytokines and their receptors as well as toxins, drugs or radionuclide delivery to MM cells. Both targeted radioimmunotherapy (RIT) and STR have proved efficient in the treatment of radiosensitive tumours. We conclude that there is a need for more mechanistic investigations of drug action to identify novel therapeutic targets in myeloma cells, as well as in the bone marrow microenvironment.
多发性骨髓瘤（MM）是一种无法治愈的终末分化浆细胞B细胞恶性肿瘤。除了传统治疗方法外，针对MM的几种靶向治疗方法也正在兴起。我们综述了基于单克隆抗体（MoAbs）和（放射性）免疫偶联物的靶向免疫治疗（血清疗法）策略以及MM中的骨骼靶向放射治疗（STR）的最新进展。基于MoAbs的策略包括靶向细胞因子及其受体以及将毒素、药物或放射性核素递送至MM细胞。靶向放射免疫疗法（RIT）和STR在放射敏感肿瘤的治疗中均已证明有效。我们得出结论，需要对药物作用进行更多的机制研究，以确定骨髓瘤细胞以及骨髓微环境中的新治疗靶点。
